Compare FBGL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | CLGN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.2M |
| IPO Year | 2022 | 2015 |
| Metric | FBGL | CLGN |
|---|---|---|
| Price | $2.25 | $3.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 104.8K | 45.8K |
| Earning Date | 11-23-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.26 |
| 52 Week High | $4.30 | $4.78 |
| Indicator | FBGL | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 52.59 |
| Support Level | $0.43 | $0.34 |
| Resistance Level | $4.30 | $3.91 |
| Average True Range (ATR) | 0.26 | 0.39 |
| MACD | -0.21 | -0.10 |
| Stochastic Oscillator | 14.31 | 30.42 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply, and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture, as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and sales of construction materials.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.